Incyte | INCY - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agenus USD 14.67M 1.35M 2026-03
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Amgen USD 653M 94.99B 2026-09
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
Eli Lilly USD 316M 201.3M 2026-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 269M 22M 2026-09
Incyte USD 605K 23K 2026-09
Ionis Pharmaceuticals USD 18M 1000K 2026-06
MacroGenics USD 4.4M 493K 2026-06
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 300K 2.6M 2026-09
Novartis USD 468M 6M 2026-09
Novartis USD 281M 8M 2025-09
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Vertex Pharmaceuticals USD 36M 32.7M 2026-09